ARTICLE | Finance
Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
October 8, 2012 7:00 AM UTC
AB Science S.A. (Euronext:AB) gained €1.52 (15%) to €11.50 after announcing EMA accepted for review an MAA for masitinib to treat Gleevec-resistant gastrointestinal stromal tumors (GIST).
Basilea Pharmaceutica AG (SIX:BSLN) was up CHF1.10 to CHF48.05 on Friday after announcing an MAA for pneumonia product ceftobiprole was accepted for review under Europe's decentralized procedure. Basilea did not disclose the reference member state conducting the review. The stock gained CHF0.55 on the week...